( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and ...
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.